Boceprevir Approval Means Better Hep C Treatment Finally Available
Share
Follow Us
The Editors at Hepatitis Central
May 16, 2011
As the first FDA approved Hepatitis C protease inhibitor, boceprevir (Victrelis) has cleared the final hurdle and can now improve the general public’s odds for beating the Hepatitis C virus.
Boceprevir Wins FDA Approval to Treat Hepatitis C
By Emily P. Walker, Washington Correspondent, MedPage Today
Published: May 13, 2011
WASHINGTON — The FDA has approved the investigational drug boceprevir (Victrelis), to be used in combination with peginterferon and ribavirin, to treat hepatitis C genotype 1.
Boceprevir, made by Merck, will be the first HCV protease inhibitor to reach market and is expected to be a major advance in treating the disease, which affects between three and four million people in U.S.
Continue reading this entire article:
http://www.medpagetoday.com/InfectiousDisease/Hepatitis/26469
